Sell-the-news reversal after FDA peptide panel votes drives HIMS plunge
Sell-the-news reversal after FDA peptide panel votes drives HIMS 12% plunge
- HIMS dropped ~12% on July 24 after rallying on FDA advisory votes
- Panel narrowly recommended several peptides (BPC-157, TB-500, KPV) for compounding list
- Non-binding recommendations led traders to lock in gains quickly
- Stock opened at $33.55, hit $34.53 high, then reversed to ~$29.50
- Hims positioned via peptide facility acquisition for potential growth
- Insider and hedge fund selling added pressure on the fade
- Classic buy-the-rumor-sell-the-news despite positive FDA outcome
- Median analyst target near $28 amid ongoing regulatory uncertainty
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.